

## Rystiggo

Abu Dhabi · access guide

# How to access Rystiggo from Abu Dhabi, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Abu Dhabi patient living with generalised myasthenia gravis (gMG) may receive a prescription for Rystiggo (rozanolixizumab-noli) from their treating neurologist or neuromuscular specialist. Rystiggo is FDA-approved for gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, and it is manufactured by UCB. It is notable as one of the first FcRn antagonists with a specific MuSK-positive indication, an important advance because MuSK-positive gMG is a clinically distinct and often more severe subtype. Rystiggo is administered as a subcutaneous infusion. In Abu Dhabi, Rystiggo may not yet be broadly registered, which is why your neurologist may be navigating a named-patient import pathway with you.

This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.

## The clinical situation

Rystiggo is administered as a weekly subcutaneous infusion over 15 minutes for six weeks (one treatment cycle), with additional cycles initiated based on clinical response and symptom fluctuation. Eligibility typically requires confirmed AChR- or MuSK-antibody seropositivity, an MGFA clinical classification, and pre-treatment screening. Your treating neurologist confirms diagnosis, screening status, and the cycle plan per FDA labeling.

## Is Rystiggo legally importable into the Abu Dhabi?

Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. The pathway allows a the Abu Dhabi-licensed (under DoH) physician to request import of a medicine not broadly registered locally when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented through a licensed importing entity.

For Rystiggo specifically, the application benefits from the subcutaneous infusion route, it can be administered in a clinic or an infusion centre, and each session is brief.

## How the pathway works, step by step

---

1. **Consultation with your treating neurologist.** AChR or MuSK antibody confirmation, gMG clinical diagnosis, MGFA classification, and pre-treatment screening.
2. **Administration facility identification.** The administering facility must be equipped for subcutaneous infusions and to manage any reaction.
3. **MoHAP named-patient application.** Your physician files the application including clinical letter, patient identifier, and product details.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner.
5. **Cold-chain shipment.** Rystiggo ships at 2-8°C with continuous temperature monitoring.
6. **Arrival and cycle administration.** The licensed facility administers the six-weekly cycle; additional cycles per clinical response.

## What documentation your physician needs

---

Your physician will typically need to provide:

- Clinical rationale letter confirming gMG diagnosis, AChR or MuSK antibody positivity, MGFA class, and prior therapy history
- Verification of the DoH medical licence (Abu Dhabi emirate)
- Identification of the administering facility
- Patient identifier
- Pre-treatment screening results and vaccination record
- Planned cycle schedule

Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for FcRn-antagonist therapy.

## Costs and timing

---

Rystiggo's US cash-pay drug-only reference price sits in a broad indicative range, the annualised treatment cost varies with cycle frequency but falls in the USD 400,000-600,000 range in US list pricing. International cold-chain logistics, MoHAP documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. Indicative range.

Indicative timing for the first cycle after cohort intake opens is 7-14 days from the moment a complete application is submitted.

*Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.*

## Reserve Meds's role

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Rystiggo specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and for MoHAP review.
- **Logistics.** Cold-chain, temperature-monitored shipment.
- **Concierge case lead.** A named point of contact.

**What we do not do:** We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

## Frequently asked

---

**Is this legal in Abu Dhabi?** Yes, when executed through the MoHAP named-patient framework with appropriate documentation.

**How does Rystiggo compare with Vyvgart for gMG?** Both are FcRn antagonists. Vyvgart is approved specifically for AChR-antibody-positive gMG and is administered IV (one hour) or as a Hytrulo subcutaneous formulation. Rystiggo is approved for both AChR-antibody- and MuSK-antibody-positive gMG and is administered as a weekly 15-minute subcutaneous infusion in six-week cycles. Patients with MuSK-positive disease often have Rystiggo specifically considered because of the broader approved label.

**What about MuSK-positive myasthenia gravis?** MuSK-positive gMG tends to have a more severe bulbar and respiratory phenotype and typically responds less well to conventional acetylcholinesterase inhibitors (pyridostigmine). The availability of an FcRn antagonist approved for MuSK-positive disease is clinically meaningful for this subgroup.

**Will private insurance cover this?** Cash-pay is the default. Some Abu Dhabi private insurers reimburse gMG biologic therapy on escalated review; we supply documentation but do not process insurance claims directly.

### *Reserve Meds's role*

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### Reserve Meds

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com